RCM
CBAY

RA Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

RA Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,940,000
Closed -$164M – 80
2023
Q4 		$164M Hold
6,940,000
– – 2.56% 8
2023
Q3 		$103M Buy
+6,940,000
New +$92M 2.04% 9

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RA Capital Management's CBAY Position: Q1 2024 in Review

RA Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 6,940,000 shares — an estimated $164M sold.

RA Capital Management first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $164M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • RA Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • RA Capital Management sold 6,940,000 Cymabay Therapeutics shares in Q1 2024, an estimated $164M.
  • RA Capital Management first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
  • RA Capital Management's Cymabay Therapeutics position peaked at $164M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.